Research
Hormonal
Continuation of GLP-1RAs did not appear to be associated with an increased incidence of residual gastric contents during EGD.
Practitioners can consider continuing GLP-1RAs during EGD without increased risk of residual gastric contents.
StrongRefutesmedium confidence
Continuing GLP-1RAs did not appear to be associated with an increased incidence of residual gastric contents.
Why this rating
Based on a retrospective study of bariatric patients undergoing EGD.
Source
Glucagon‐like peptide‐1 receptor agonists and upper endoscopy: a real‐world experience
Pichamol Jirapinyo et al. · Obesity · 2025
DOI 10.1002/oby.24190
cohort · n=629Cited 6×
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
More from this paper
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →